Tumor cell recognition by lymphocytes: Is the MHC always essential?

Critical Reviews in Immunology

Volumn 18, Issue 1-2, 1997, Pages 139-144

  Packard, Beverly Z ^a   Komoriya, Akira ^a  

^a Oncolmmunin Inc   (United States)

Author keywords

Adoptive immunotherapy; Cancer; Myeloid cells; Serpins; T cells; TILs

Indexed keywords

ELASTASE INHIBITOR; LEUKOCYTE ELASTASE; MAJOR HISTOCOMPATIBILITY ANTIGEN; ONCOIMMUNIN L; ONCOPROTEIN; UNCLASSIFIED DRUG; GROWTH PROMOTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSURVEILLANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; T LYMPHOCYTE ACTIVATION; ARTICLE; CELL CULTURE; FORECASTING; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; TUMOR ASSOCIATED LEUKOCYTE;

FORECASTING; GROWTH SUBSTANCES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030723014     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Kruit, W. H. and Stoter, G., The role of adoptive immunotherapy in solid cancers, Neth. J. Med., 50, 47, 1997.
2. Searle, P. F. and Young, L. S., Immunotherapy, II. Antigens, receptors and costimulation, Cancer Metastasis Rev., 15, 329, 1996.
3. Fenton, R. G. and Longo, D. L., Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes, J. Natl. Cancer Inst., 89, 272, 1997.
4. Schoenberger, S. P. and Sercarz, E. E., Harnessing self-reactivity in cancer immunotherapy, Sermin. Immunol., 8, 303, 1996.
5. Srivastava, P. K., Do human cancers express shared protectivve antigens? or the necessity of remembrance of things past, Semin. Immunol., 8, 295, 1996.
6. Kershaw M. H.,Trapani, J. A., and Smyth, M. J., Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer, Ther. Immunol., 2, 173, 1995.
7. Smyth, M. J. and Kershaw, M. H., Cytotoxic lymphocyte-mediated immunotherapy, Aust. N.Z. J. Med, 25, 852, 1995.
8. Melief, C. J. and Kast, W. M., T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes, Immunol. Rev., 145, 167, 1995.
9. Sznol, M. and Urba, W. J., Adoptive immunotherapy, Cancer Chemother. Biol. Response Modif., 15, 213, 1994.
10. S. A. Rosenberg, Packard, B, S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P., and White, D. E., Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, N. Engl. J. Med., 319, 1676, 1988.
11. Packard B. S., The use of tumor-infiltrating lymphocytes in cancer therapy, in Progress in Regional Cancer Therapy, Jakesz, R. and Rainer, H., Eds., 1990, 293.
12. 111Indium-labeled tumor infiltrating lymphocytes in patients with advanced cancer, J. Clin. Oncol., 7, 250, 1989.
13. Griffith, K. D., Read, E. J., Carrasquillo, J. A., Carter, C. S., Yang, J. C., Fisher, B., Aebersold, P., Yu, J. Y., Packard, B. S., and Rosenberg, S. A., In vivo distribution of adoptively transferred "Indium-labeled tumor-infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma, J. Natl. Cancer Inst., 81, 1709, 1979.
14. Blankenstein, T., Observations with tumour necrosis factor gene-transfected tumors, Folia Biol., 40, 19, 1994.
15. Hwu, P. and Rosenberg, S. A., The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy, Ann. N.Y. Acad. Sci., 716, 188, 1994.
16. Fleuren, G. J., Gorter, A., Kuppen, P. J., Litvinov, S., and Warnaar, S. O., Tumor heterogeneity and immunotherapy of cancer, Immunol. Rev., 145, 91, 1995.
17. Packard, B. S., Mitogenic stimulation of human tumor-infiltrating lymphocytes by secreted factor(s) from human tumor cell lines, Proc. Natl. Acad. Sci. U.S.A., 87, 4058, 1990.
18. Edelman, G. M., Topobiology: An Introduction to Molecular Embryology, Basic Books, New York, 1988.
19. Packard, B. Z. and Komoriya, A., Oncoimmunins: new tumor-derived cytokines with immunomodulatory activity, FASEB J., 6, A68, 1992; Science, 255, 1645, 1992.
20. Packard, B. Z. and Komoriya, A., Oncoimmunins: new tumor-derived cytokines with immunomodulatory activity, FASEB J., 6, A68, 1992; Science, 255, 1645, 1992.
21. Packard, B. Z., Lee, S. S., Remold-O'Donnell, E., and Komoriya, A., A Serpin from human tumor cells with direct lymphoid immunomodulatory activity: mitogenic stimulation of human tumor-infiltrating lymphocytes, Biochim. Biophys. Acta, 1269, 41, 1995.
22. Stein, P. E. and Carrell, R. W., What do dysfunctional serpins tell us about molecular mobility and disease? Nature Struct. Biol., 2, 96, 1995.
23. Wright, H. T., The structural puzzle of how serpin serine proteinase inhibitors work, Biaessays, 18, 453, 1996.
24. Potempa, J., Korzus, E., and Travis, J., The serpin superfamily of proteinase inhibitors: structure, function, and regulation, J. Biol. Chem., 269, 15957, 1994.
25. Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A. et al., Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells, Science, 263, 526, 1994.
26. Sheng, S., Pemberton, P. A., and Sager, R., Production, purification, and characterization of recombinant maspin proteins, J. Biol. Chem., 269, 30988, 1994.
27. Pemberton, P. A., Wong, D. T., Gibson, H. L., Kiefer, M. C., et al., The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases, J. Biol. Chem., 270, 15832, 1995.
28. Remold-O'Donnell, E., The ovalbumin family of serpin proteins, FEBS, 2, 105, 1993.
29. Packard, B. Z. and Komoriya, A., A 36-kilodalton tumor-derived factor with myeloid immunomodulatory activity, J. Biol. Chem., 268, 6356, 1993.
30. Packard, B. Z., Upregulation of two integrins and induction of chemotactic activity in a human leukemic cell line by Oncoimmunin-M, Biochim. Biophys. Acta, 1222, 159, 1994.
31. Packard, B. Z., A role for intracellular components of target cells in activation of the immunosurveillance network, Biotech. Therapeut., 5, 127, 1995.
32. Roth, J. A. and Cristiano, R. J., Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst., 89, 21, 1997.
33. Rosenberg, S. A., Cancer vaccines based on the identification of genes encoding cancer regression antigens, Immunol. Today, 18, 175, 1997.
34. Baskar, S., Gene-modified tumor cells as cellular vaccine, Cancer Immunol. Immunother., 43, 165, 1996.
35. Celis, E., Sette, A., and Grey, H. M., Epitope selection and development of peptide based vaccines to treat cnacer, Semin. Cancer Biol., 6, 329, 1995.
36. Chang, A. E. and Shu, S., Current status of adoptive immunotherapy of cancer, Crit. Rev. Oncol. Hematol., 22, 213, 1996.
37. Hess, P., Gene therapy: a brief review, Clin. Lab. Med., 16, 197, 1996.
38. Lattime, E. C., Lee, S. S., Eisenlohr, L. C., and Mastrangelo, M. J., In situ cytokine gene transfection using vaccinia virus vectors, Semin. Oncol., 23, 88, 1996.
39. Gilboa, E., Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol., 23, 101, 1996.
40. Nabel, G. J., Yang, Z. Y., Mabel, E. G., Bishop, K. et al., Direct gene transfer for treatment of human cancer, Ann. N.Y. Acad. Sci., 772, 227, 1995.
41. Jaffee, E. M. and Pardoll, D. M., Gene therapy: its potential applications in the treatment of renal cell carcinoma, Semin. Oncol., 22, 81, 1995.
42. Vieweg, J. and Gilboa, E., Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment, Cancer Invest., 13, 193, 1995.
43. Akiyoshi, T., Cancer vaccine therapy using peptides derived from tumor rejection antigens, Gan To Kagaku Ryoho, 24, 511, 1997.
44. Slingluff, C. L., Jr., Tumor antigens and tumor vaccines: peptides as immunogens, Semin. Surg. Oncol., 12, 446, 1996.
45. Jones, V. E. and Mitchell, M. S., Therapeutic vaccines for melanoma: progress and problems, Trends Biotechnol., 14, 349, 1996.
46. Linehan, D. C., Goedegebuure, P. S., and Eberlein, T. J., Vaccine therapy for cancer, Ann. Surg. Oncol., 3, 219, 1996.
47. Dalgleish, A. G., Cancer vaccines, Eur. J. Cancer, 30, 1029, 1994.
48. Bartholeyns, J. and Lopez, M., Immune control of neoplasia by adoptive transfer of macrophages: potentiality for antigen presentation and gene transfer, Anticancer Res., 14(6B), 2673, 1994.
49. B. Z. Packard and G. Parry., Bone marrow activation by immobilized antibodies against tumor cells and immunocytes as a potential cancer immunotherapy, Biochim. Biophys. Acta, 1224, 395, 1994.